Medifast (NYSE:MED) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened

Medifast Inc (NYSE:MED - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.21 and traded as high as $12.20. Medifast shares last traded at $12.0260, with a volume of 62,331 shares changing hands.

Wall Street Analyst Weigh In

• LifeMD Can Surge on Its GLP-1 Offerings

Several analysts have weighed in on the company. Weiss Ratings raised Medifast from a "sell (e+)" rating to a "sell (d)" rating in a report on Monday, August 17th. Zacks Research lowered shares of Medifast from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Reduce" and a consensus target price of $12.00.

Get Our Latest Analysis on MED

Medifast Trading Down 0.1%

• LifeMD Shares Come Back to Life on GLP-1 Business Growth

The stock has a 50 day moving average price of $11.34 and a two-hundred day moving average price of $11.21. The company has a market cap of $134.45 million, a price-to-earnings ratio of -5.16 and a beta of 0.71.

Medifast (NYSE:MED - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million during the quarter, compared to analysts' expectations of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. On average, equities analysts forecast that Medifast Inc will post -1.04 EPS for the current fiscal year.

Insider Activity

• Are These Consumer Staples Too Cheap for Investors To Ignore?

In related news, Director Parsa Kiai bought 43,150 shares of the firm's stock in a transaction dated Wednesday, August 26th. The stock was bought at an average cost of $12.26 per share, for a total transaction of $529,019.00. Following the transaction, the director owned 707,492 shares of the company's stock, valued at $8,673,851.92. This represents a 6.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders bought 119,966 shares of company stock worth $1,423,576. 3.70% of the stock is currently owned by insiders.

Institutional Trading of Medifast

Hedge funds have recently modified their holdings of the company. State of Wyoming increased its stake in Medifast by 19.8% in the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer's stock valued at $68,000 after purchasing an additional 1,097 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Medifast in the second quarter worth $75,000. Ieq Capital LLC bought a new position in shares of Medifast during the second quarter worth $114,000. Squarepoint Ops LLC bought a new position in shares of Medifast during the second quarter worth $214,000. Finally, Chico Wealth RIA acquired a new position in shares of Medifast in the 2nd quarter valued at $223,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

About Medifast

(Get Free Report)

Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.

Recommended Stories

• Five stocks we like better than Medifast
• Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
• Institutional Money Is Pouring Into These 2 Altcoin ETFs
• The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
• 3 Dividend Kings to Buy While They’re Still Beaten Down

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medifast Right Now?

Before you consider Medifast, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.

While Medifast currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here